Reply to: ‘‘Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis!’’  by Forner, Alejandro et al.
can authors state that recurrence is due to the ‘‘malignant proﬁle’’
if nodules had been resected or ablated and ‘‘classiﬁed as necro-
tic’’? Is it not possible that distant recurrences were due to the
well-known hepatocarcinogenesis of HCC on cirrhosis?
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Forner A, Vilana R, Bianchi L, Rodríguez-Lope C, Reig M, García-Criado MA,
et al. Lack of arterial hypervascularity at contrast-enhanced ultrasound
should not deﬁne the priority for diagnostic work-up of nodules <2 cm. J
Hepatol 2015;62:150–155. http://dx.doi.org/10.1016/j.jhep.2014.08.028.
[2] Floriani I, D’Onofrio M, Rulli E, Chen MH, Li R, Musicco L. Performance of
imaging modalities in the diagnosis of hepatocellular carcinoma: a systematic
review and meta-analysis. Ultraschall Med 2013;34:454–462. http://
dx.doi.org/10.1055/s-0032-1330358.
[3] Blondin D, Erhardt A, Crynen K, Sagir A, Scherer A, Kröpil P, et al. Diagnosis of
focal liver lesions in cirrhotic patients: comparison of contrast-enhanced
ultrasound using sulphur hexaﬂuoride (SF6) microbubbles and MRI using Gd-
EOB-DTPA. Z Gastroenterol 2011;49:23–29. http://dx.doi.org/10.1055/s-
0029-1245781.
[4] Giorgio A, De Stefano G, Coppola C, Ferraioli G, Esposito V, Di Sarno A, et al.
Contrast-enhanced sonography in the characterization of small hep-
atocellular carcinomas in cirrhotic patients: comparison with contrast-
enhanced ultrafast magnetic resonance imaging. Anticancer Res
2007;27:4263–4269.
[5] Zhang Xiao-Yun, Luo Yan, Wen Tian-Fu, Jiang Li, Li Chuan, Zhong Xiao-Fei,
et al. Contrast-enhanced ultrasound: Improving the preoperative staging of




Interventional Ultrasound Unit, Tortorella Clinical Institute,
ISSMES Consortium, Salerno, Italy⇑Corresponding author.
E-mail address: agiorgio28@gmail.com
Valentina Giorgio
Catholic University of sacred Heart, Rome, Italy
Paolo Matteucci
Campus Biomedico University, Rome, Italy
JOURNAL OF HEPATOLOGYReply to: ‘‘Poor contrast enhanced ultrasonography! There is no limit
to its decline in the diagnosis of hepatocellular carcinoma
on cirrhosis!’’To the Editor:
We would like to thank Giorgio et al. for their interest in our
recent study about the role of contrast-enhanced ultrasound
(CEUS) in the diagnostic process of small nodules detected during
screening US [1]. In this study, the main conclusion was that the
absence of contrast hyperenhancement during the arterial phase
at CEUS does not predict a less malignant proﬁle and thus, prior-
ity for diagnostic work-up and treatment should not differ
according to contrast proﬁle at CEUS. The letter by Giorgio et al.
criticised some methodological aspects of our study and they
claim that CEUS still has an important role in the diagnostic recall
strategy upon the detection of a nodule by screening US. The ﬁrst
concern raised in the letter was the use of the non-invasive
diagnostic criteria by MRI after 2007 as gold standard for HCC
conclusive diagnosis. Since the non-invasive HCC diagnosis by
imaging has been extensively and prospectively validated, and
fully accepted by the main scientiﬁc societies [2,3] and the
Spanish guidelines for HCC management [4], Giorgio et al. will
surely agree with us that delaying the HCC diagnosis and treat-
ment until histological conﬁrmation is ethically questionable. In
addition, we would like to highlight that in only 14 out of 119
(11.7%) HCC lesions the ﬁnal diagnosis was based only on imag-
ing criteria, and all 18 HCC lesions with absence of arterial con-
trast hyperenhancement detection at CEUS were histologically
conﬁrmed. Moreover, Giorgio et al. summarize some studiesJournal of Hepatology 20
Open access under CC BY-NC-ND license.aimed to evaluate the diagnostic accuracy of CEUS alone or
associated to CT/MRI for HCC diagnosis, emphasizing that CEUS
showed the best diagnostic accuracy. This is not surprising since
the combination of imaging techniques is always associated with
better speciﬁcity than when just only one imaging technique,
whatever one is used. Furthermore, Giorgio et al. questioned
the feasibility of cytology for diagnosing intrahepatic
cholangiocarcinoma and dysplastic nodules. However, the sam-
ples were processed in cell-block; this allows the assessment of
cyto-histological ﬁndings and the use of immunohistochemistry
markers, which permits the diagnosis of both entities [5,6].
Regarding the feasibility of CEUS, in the 5 cases (3%) men-
tioned the nodule was deeply located with a poor sonographic
window and despite that the nodule was previously visualized
by US, a reliable CEUSwas not possible. This is not surprising since
our study was prospective and the inclusion criteria was the iden-
tiﬁcation of a solitary nodule smaller than 2 cm by screening US
and not by CEUS exploration, and expert radiologists will agree
that not all US visible nodules can be explored by CEUS.
Giorgio et al. also claim data regarding the diagnostic accuracy
of MRI. We would like to stress that our study is not aimed to
assess the diagnostic accuracy of MRI, or compared it with
CEUS, since this information has been previously reported [7,8].
As requested, in our cohort of patients, MRI did not identify the
target nodule in 25 out of 168 patients (14.8%), but only 3 of these15 vol. 62 j 1438–1454 1453
nodules were HCC. Contrarily, MRI identiﬁed other nodules in 39
patients, 7 of them being additional HCC focus unidentiﬁed by
CEUS. Finally, Giorgio et al. suggest that most recurrence might
be due to de novo HCC arising from an oncogenic cirrhotic liver.
However, 2 out of 3 recurrences after resection and 2 distal recur-
rence after ablation were detected within the ﬁrst 6 months, and
2 recurrences in ablated patients appeared in the treated nodule
(and in one case also associated with distal recurrence). These 6
cases (out of 10 cases of recurrence) reﬂect a malignant nature
with invasive potential.
In summary, we hope that these comments help to clarify
some of the controversies raised by Giorgio et al., while also
exposing that the evaluation and management of the patients
as per risk of cancer progression and death, should not be differ-
ent from the process with CEUS positive patients.
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